Esperion Announces Positive Phase 2 Clinical Trial Results for ETC-1002Esperion Therapeutics, a privately held biotechnology company in Plymouth, Monday announced positive results from a Phase 2 clinical trial for its potential cholesterol buster, ETC-1002.

More From CBS Detroit

Hump Day Drinks: 8 Cheery Cocktail RecipesNow that you've made it through half the work week, it's time to celebrate!
Daily J

Watch & Listen